AAV Research and Development Gene Therapy

Bedrock Therapeutics is focused on advancing gene therapy through its innovative technologies, particularly in the development of human-tropic and antibody-evading adeno-associated virus (AAV) capsids. These specialized capsids are designed to enhance the delivery of therapeutic genes to target cells while minimizing immune responses that could hinder treatment efficacy. By utilizing these advanced AAV capsids, Bedrock aims to improve the safety and effectiveness of gene therapies, making them more accessible for a wider range of genetic disorders.

In addition to its work with AAV capsids, Bedrock Therapeutics is also developing Single Chain Immune Modulators (scIMs). These modulators are engineered to interact with the immune system in a way that can potentially enhance the therapeutic effects of gene therapies while reducing unwanted immune reactions. This dual approach of utilizing both advanced AAV technology and immune modulation positions Bedrock Therapeutics at the forefront of gene therapy innovation, with the goal of delivering more effective treatments for patients with genetic conditions.

United States

Bedrock Therapeutics is an AAV gene therapy research and development company developing platform and disease specific technologies for the treatment of ocular, hematologic, and other diseases. Drs. Matt Hirsch, Chenwen Li, Bryan Sutton, and Brian Gilger are co-founders of Bedrock. Drs. Gilger and Hirsch oversee the de novo design and validation of ocular assets, and Drs. Li and Sutton oversee basics aspects of the various host immune responses to AAV vectors and protein engineering and design.

Bedrock Therapeutics

Company Details